Press Release April 05, 2021

Ikena Oncology Announces Closing Of $143.8 Million Initial Public Offering And Exercise In Full Of The Underwriters’ Option To Purchase Additional Shares

The Life Sciences team advised Ikena Oncology, Inc. (Nasdaq: IKNA) on its initial public offering of 8,984,375 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,171,875 additional shares of common stock, at a public offering price of $16.00 per share. The aggregate gross proceeds to Ikena from the offering were approximately $143.8 million, before deducting underwriting discounts and commissions and other offering expenses.

Ikena is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer.

The Goodwin team was led by Richard Hoffman, Stephanie Richards, William Collins, Christopher Huntsman and Martha Koroshetz, and included Alexandra Denniston, James Devendorf, Elizabeth Doyon, Stephanie Philbin, Sarah Wicks, Roger Cohen, Delphine O’Rourke, Madison Marcus, Duncan Greenhalgh, Megan Gustafson, Robert Hale, Caroline Galiatsos, Janet Andolina, Claire Oxford, Caroline Bullerjahn, Tim Worden, Lucy Sharples, Jackie Klosek, and Mark Burnett, with invaluable assistance from Coleen Doyle and Nathan Needle.

For more details, read the press release and articles in Barron’s, Seeking Alpha, and BioSpace.